As a pharmacist, one could imagine that the issue of compounding a medicine for which there is widespread patient need would be an opportunity, not a problem.
Pharmacists of a “certain age” spent a lot of time when we were in pharmacy school in the compounding lab learning how to perform a function that was a cornerstone to our profession; making the medicine the doctor ordered for the patient. Fast forward: there is very little emphasis on compounding in pharmacy schools and most pharmacists spend very little time compounding the medicines their doctors prescribe.
Pharmacists focus most of their time on helping patients make the best use of their medicines, not making them. We rely of the well-established pharmaceutical industry to create, develop, and manufacture medicines that formerly were compounded.
What concerns me is the widespread, large-scale preparation of commercially available medicines under the guise of “compounding” in “compounding pharmacies.” These enterprises are skirting FDA oversight by functioning as surrogate manufacturers with none of the regulations that assure patient safety with products from the pharmaceutical industry. Substandard practices and errors that can and have occurred in these unregulated compounding pharmacies can and have resulted in patient harm, including deaths.
As a pharmacist, I am NOT caught in the debate about strengthening oversite over compounding pharmacies.
The recently announced FDA crackdown on compounding pharmacies and legislative initiative including the SAFE Drug Act are encouraging developments that will protect the public from the harm than can result from an affront to the Oath of the Pharmacist that states: “I will hold myself and my colleagues to the highest principles of our profession’s moral, ethical and legal conduct.”
By Philip Schneider, MS FASHP FFIP
Related Articles
5 Things to Know About the FDA’s Peptide Reversal
Author(s)Habiba Atta Fact checked by: Laura Joszt, MA FDA advisers overrode their own scientists to back 6 peptides for compounding, even as safety data remains thin and gray-market risks persist. When a reconstituted FDA advisory panel voted in late July to recommend...
Retatrutide 101: What Consumers Should Know About the Growing Online Market
Interest in next-generation obesity medicines is accelerating rapidly — and so is the online marketplace claiming to sell them. One of the latest examples is retatrutide, an investigational therapy currently being studied in clinical trials but increasingly promoted...
Impurity Found in Compounded GLP-1 Drugs Underscores Importance of FDA Oversight
Philip Schneider, MS FASHP FFIP As a pharmacist, my priority is helping patients benefit from medicines, and protect them from harm caused by medicines intended to help them. This week we saw an example of why the oversight of the U.S. Food and Drug Administration...